Repligen (RGEN) to Release Quarterly Earnings on Tuesday

Repligen (NASDAQ:RGEN - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, April 29th. Analysts expect the company to announce earnings of $0.35 per share and revenue of $163.65 million for the quarter. Repligen has set its FY 2025 guidance at 1.630-1.720 EPS.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business's revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.28 EPS. On average, analysts expect Repligen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Price Performance

NASDAQ RGEN traded down $1.44 on Wednesday, hitting $137.99. The company had a trading volume of 975,539 shares, compared to its average volume of 719,845. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company's fifty day moving average price is $139.19 and its 200-day moving average price is $145.93. The company has a market capitalization of $7.75 billion, a PE ratio of -270.57, a PEG ratio of 4.54 and a beta of 1.27. Repligen has a 12-month low of $102.97 and a 12-month high of $182.52.

Analyst Ratings Changes

A number of research analysts recently weighed in on RGEN shares. Royal Bank of Canada decreased their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research note on Wednesday. HC Wainwright reissued a "buy" rating and set a $180.00 target price on shares of Repligen in a report on Friday, February 21st. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a research note on Tuesday. JPMorgan Chase & Co. reduced their price objective on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday. Finally, TD Cowen began coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $173.25.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax acquired 250 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.